Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mix and Match COVID-19 Booster Study
NCT04889209Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of elasomeran, tozinameran, Ad26.COV2.S, NVX-CoV2373, mRNA-1273.211 in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2021; status: completed.
02
Drugs
elasomerantozinameranAd26.COV2.SNVX-CoV2373mRNA-1273.211
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04889209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889209.